NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a specific tyrosine kinase receptor inhibitor that is used in the therapy of philadelphia chromosome-positive chronic myelogenous leukemia and inhibits the receptor tyrosine kinases for PDGF in SSc [99].